Free Trial

Dynavax Technologies Q4 2022 Earnings Report

Dynavax Technologies logo
$12.72 -0.04 (-0.31%)
(As of 12/20/2024 05:16 PM ET)

Dynavax Technologies EPS Results

Actual EPS
$0.45
Consensus EPS
$0.46
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Dynavax Technologies Revenue Results

Actual Revenue
$184.49 million
Expected Revenue
$184.20 million
Beat/Miss
Beat by +$290.00 thousand
YoY Revenue Growth
N/A

Dynavax Technologies Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Dynavax Technologies Earnings Headlines

First JFK… next Elon?
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
See More Dynavax Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dynavax Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dynavax Technologies and other key companies, straight to your email.

About Dynavax Technologies

Dynavax Technologies (NASDAQ:DVAX), a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

View Dynavax Technologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings